{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:59:02Z","timestamp":1791824342058,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["962815"],"award-info":[{"award-number":["962815"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04378-0","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:15:04Z","timestamp":1782195304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In silico repurposing of clinically approved drugs as potential BRAF inhibitors: a pharmacophore-based virtual screening and experimental investigation"],"prefix":"10.1186","volume":"26","author":[{"given":"Hooriehsadat","family":"Amini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayedali","family":"Mousavirahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhdeh","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kowsar","family":"Bagherzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homa","family":"Azizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"1\u20132","key":"4378_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0248-4900(01)01125-x","volume":"93","author":"C Peyssonnaux","year":"2001","unstructured":"Peyssonnaux C, Eych\u00e8ne A. The Raf\/MEK\/ERK pathway: new concepts of activation. Biol Cell. 2001;93(1\u20132):53\u201362. https:\/\/doi.org\/10.1016\/s0248-4900(01)01125-x.","journal-title":"Biol Cell"},{"issue":"8","key":"4378_CR2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.bbamcr.2007.05.001","volume":"1773","author":"DT Leicht","year":"2007","unstructured":"Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, et al. Raf kinases: function, regulation, and role in human cancer. Biochim Biophys Acta. 2007;1773(8):1196\u2013212. https:\/\/doi.org\/10.1016\/j.bbamcr.2007.05.001.","journal-title":"Biochim Biophys Acta"},{"key":"4378_CR3","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00018-006-6005-y","volume":"63","author":"A Zebisch","year":"2006","unstructured":"Zebisch A, Troppmair J. Back to the roots: the remarkable RAF oncogene story. Cell Cell Mol Life Sci. 2006;63:1314\u201330.","journal-title":"Cell Cell Mol Life Sci"},{"issue":"4646","key":"4378_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.6324342","volume":"224","author":"GE Mark","year":"1984","unstructured":"Mark GE, Rapp UR. Primary structure of v-raf: relatedness to the src family of oncogenes. Science. 1984;224(4646):285\u20139. https:\/\/doi.org\/10.1126\/science.6324342.","journal-title":"Science"},{"issue":"5","key":"4378_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4161\/sgtp.2.5.17740","volume":"2","author":"MM McKay","year":"2011","unstructured":"McKay MM, Freeman AK, Morrison DK. Complexity in KSR function revealed by Raf inhibitor and KSR structure studies. Small GTPases. 2011;2(5):276\u201381. https:\/\/doi.org\/10.4161\/sgtp.2.5.17740.","journal-title":"Small GTPases."},{"key":"4378_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0065-230X(04)91005-6","volume":"91","author":"G Odabaei","year":"2004","unstructured":"Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169\u2013200. https:\/\/doi.org\/10.1016\/S0065-230X(04)91005-6.","journal-title":"Adv Cancer Res"},{"issue":"2","key":"4378_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/s0955-0674(97)80060-9","volume":"9","author":"DK Morrison","year":"1997","unstructured":"Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol. 1997;9(2):174\u20139. https:\/\/doi.org\/10.1016\/s0955-0674(97)80060-9.","journal-title":"Curr Opin Cell Biol"},{"issue":"7343","key":"4378_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature09860","volume":"472","author":"DF Brennan","year":"2011","unstructured":"Brennan DF, Dar AC, Hertz NT, Chao WCH, Burlingame AL, Shokat KM, et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature. 2011;472(7343):366\u20139. https:\/\/doi.org\/10.1038\/nature09860.","journal-title":"Nature"},{"issue":"8","key":"4378_CR9","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent anti-melanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041\u20136. https:\/\/doi.org\/10.1073\/pnas.0711741105.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4378_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","volume":"6","author":"MJ Garnett","year":"2004","unstructured":"Garnett MJ, Marais R. Guilty as charged; B-RAF is a human oncogene. Cancer Cell. 2004;6:313\u20139.","journal-title":"Cancer Cell"},{"issue":"6","key":"4378_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/s0092-8674(04)00215-6","volume":"116","author":"PTC Wan","year":"2004","unstructured":"Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855\u201367. https:\/\/doi.org\/10.1016\/s0092-8674(04)00215-6.","journal-title":"Cell"},{"issue":"11","key":"4378_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875\u201385. https:\/\/doi.org\/10.1038\/nrm1498.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"4378_CR13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3392","volume":"19","author":"P Lito","year":"2013","unstructured":"Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401\u20139. https:\/\/doi.org\/10.1038\/nm.3392.","journal-title":"Nat Med"},{"issue":"8","key":"4378_CR14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3390\/cancers11081197","volume":"11","author":"A Zaman","year":"2019","unstructured":"Zaman A, Wu W, Bivona TG. Targeting oncogenic BRAF: Past, present, and future. Cancers (Basel). 2019;11(8):1197. https:\/\/doi.org\/10.3390\/cancers11081197.","journal-title":"Cancers (Basel)"},{"issue":"6892","key":"4378_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"issue":"4","key":"4378_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1158\/1535-7163.mct-15-0643","volume":"15","author":"ML Turski","year":"2016","unstructured":"Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, et al. Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a paradigm. Mol Cancer Ther. 2016;15(4):533\u201347. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0643.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"4378_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/fon.12.43","volume":"8","author":"K Young","year":"2012","unstructured":"Young K, Minchom A, Larkin J. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol. 2012;8(5):499\u2013507. https:\/\/doi.org\/10.2217\/fon.12.43.","journal-title":"Future Oncol"},{"issue":"8","key":"4378_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2017.43.","journal-title":"Nat Rev Clin Oncol"},{"key":"4378_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","volume":"62","author":"SJ Welsh","year":"2016","unstructured":"Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next? Eur J Cancer. 2016;62:76\u201385. https:\/\/doi.org\/10.1016\/j.ejca.2016.04.005.","journal-title":"Eur J Cancer"},{"key":"4378_CR20","doi-asserted-by":"crossref","unstructured":"Barras D. BRAF Mutation in colorectal cancer: an update., biomark, cancer. Biomark, Cancer. 2015;9\u201312.","DOI":"10.4137\/BIC.S25248"},{"key":"4378_CR21","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0057","author":"KB Kim","year":"2013","unstructured":"Kim KB, Cabanillas ME, Lazar AJ, Sherman YSI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer Harboring BrafV600E mutation. Thyroid. 2013. https:\/\/doi.org\/10.1089\/thy.2013.0057.","journal-title":"Thyroid"},{"issue":"5","key":"4378_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrm3979","volume":"16","author":"H Lavoie","year":"2015","unstructured":"Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol [Internet]. 2015;16(5):281\u201398. https:\/\/doi.org\/10.1038\/nrm3979.","journal-title":"Nat Rev Mol Cell Biol [Internet]."},{"issue":"3","key":"4378_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","volume":"30","author":"Z Karoulia","year":"2016","unstructured":"Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell. 2016;30(3):485\u201398. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.024.","journal-title":"Cancer Cell"},{"issue":"3","key":"4378_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1158\/2159-8290.CD-15-0896","volume":"6","author":"S-H Chen","year":"2016","unstructured":"Chen S-H, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, et al. Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discov. 2016;6(3):300\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0896.","journal-title":"Cancer Discov"},{"issue":"7","key":"4378_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.1257","volume":"9","author":"H Lavoie","year":"2013","unstructured":"Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S, et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol. 2013;9(7):428\u201336. https:\/\/doi.org\/10.1038\/nchembio.1257.","journal-title":"Nat Chem Biol"},{"key":"4378_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26\u201348. https:\/\/doi.org\/10.1016\/j.phrs.2015.10.021.","journal-title":"Pharmacol Res"},{"issue":"19","key":"4378_CR27","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1016\/j.bmcl.2012.08.007","volume":"22","author":"S Wenglowsky","year":"2012","unstructured":"Wenglowsky S, Moreno D, Laird ER, Gloor SL, Ren L, Risom T, et al. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors. Bioorg Med Chem Lett. 2012;22(19):6237\u201341. https:\/\/doi.org\/10.1016\/j.bmcl.2012.08.007.","journal-title":"Bioorg Med Chem Lett"},{"key":"4378_CR28","unstructured":"Schr\u00f6dinger Release 2018\u20104: Protein preparation wizard; Epik, Schr\u00f6dinger, LLC, New York, NY, 2018."},{"key":"4378_CR29","unstructured":"Schr\u00f6dinger Release 2018\u20104: LigPrep, Schr\u00f6dinger, LLC, New York, NY, 2018."},{"key":"4378_CR30","unstructured":"Schr\u00f6dinger Release 2018\u20104: Phase, Schr\u00f6dinger, LLC, New York, NY, 2018."},{"key":"4378_CR31","unstructured":"Schr\u00f6dinger Release 2018\u20104: Induced fit docking protocol; glide, schr\u00f6dinger, LLC, New York, NY, 2018; Prime, Schr\u00f6dinger, LLC, New York, NY, 2018."},{"key":"4378_CR32","unstructured":"Schr\u00f6dinger Release 2018\u20104: Virtual screening workflow, glide, schr\u00f6dinger, LLC, New York, NY, 2018; Prime, Schr\u00f6dinger, LLC, New York, NY, 2018."},{"key":"4378_CR33","unstructured":"Schr\u00f6dinger Release 2018\u20104: Desmond molecular dynamics system, d. e. shaw research, New York, NY, 2018; Maestro desmond interoperability tools, schr\u00f6dinger, New York, NY, 2018."},{"issue":"2","key":"4378_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1021\/ci050481b","volume":"46","author":"AB Wagner","year":"2006","unstructured":"Wagner AB. SciFinder Scholar 2006: an empirical analysis of research topic query processing. J Chem Inf Model. 2006;46(2):767\u201374. https:\/\/doi.org\/10.1021\/ci050481b.","journal-title":"J Chem Inf Model"},{"key":"4378_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2017.1317025","author":"P Verma","year":"2017","unstructured":"Verma P, Tiwari M, Tiwari V. In-silico high throughput virtual screening and molecular dynamics simulation study to identify inhibitor for AdeABC efflux pump of acinetobacter baumannii. J Biomol Struct Dyn. 2017. https:\/\/doi.org\/10.1080\/07391102.2017.1317025.","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"4378_CR36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11030-013-9473-7","volume":"17","author":"H Zhang","year":"2013","unstructured":"Zhang H, Xiang M-L, Liang J-Y, Zeng T, Zhang X-N, Zhang J, et al. Combination of pharmacophore hypothesis, genetic function approximation model, and molecular docking to identify novel inhibitors of S6K1. Mol Divers. 2013;17(4):767\u201372. https:\/\/doi.org\/10.1007\/s11030-013-9473-7.","journal-title":"Mol Divers"},{"key":"4378_CR37","unstructured":"DUD-E: A database of useful (docking) decoys \u2014 enhanced [Internet]. Docking.org. [cited 2024 Sep 15]. Available from: https:\/\/dude.docking.org\/"},{"key":"4378_CR38","unstructured":"ChEMBL Database. Ebi.ac.uk. [cited 2024 Sep 15]. Available from: https:\/\/www.ebi.ac.uk\/chembl\/"},{"key":"4378_CR39","unstructured":"E-Drug3D. Available from: https:\/\/chemoinfo.ipmc.cnrs.fr\/MOLDB\/index.php"},{"key":"4378_CR40","unstructured":"RCSB Protein Data Bank. RCSB PDB: Homepage. Rcsb.org. [cited 2024 Sep 15]. Available from: https:\/\/www.rcsb.org\/"},{"issue":"1","key":"4378_CR41","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/cancers12010250","volume":"12","author":"O Elaskalani","year":"2020","unstructured":"Elaskalani O, Domenchini A, Abdol Razak NB, Dye DE, Falasca M, Metharom P. Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT Pathway in pancreatic cancer cells. Cancers. 2020;12(1):250.","journal-title":"Cancers"},{"issue":"7","key":"4378_CR42","doi-asserted-by":"publisher","first-page":"11971","DOI":"10.1038\/ncomms11971","volume":"20","author":"Y Hao","year":"2016","unstructured":"Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat Commun. 2016;20(7):11971.","journal-title":"Nat Commun"},{"issue":"9","key":"4378_CR43","doi-asserted-by":"crossref","first-page":"101042831772162","DOI":"10.1177\/1010428317721620","volume":"39","author":"AX Toress-Collado","year":"2017","unstructured":"Toress-Collado AX, Nazarian R, Jazirehi AR. Rescue of cell cycle progression in BRAF(V600E) inhibitor-resistant human melanoma by a chromatin modifier. Tumour Biol. 2017;39(9):1010428317721620.","journal-title":"Tumour Biol"},{"issue":"10","key":"4378_CR44","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/cncr.20574","volume":"101","author":"A Reichle","year":"2004","unstructured":"Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer. 2004;101(10):2247\u201356.","journal-title":"Cancer"},{"issue":"5","key":"4378_CR45","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10528-016-9754-9","volume":"54","author":"I Elmaci","year":"2016","unstructured":"Elmaci I, Altinoz MA. A metabolic inhibitory cocktail for grave cancers: metformin, pioglitazone and lithium combination in treatment of pancreatic cancer and glioblastoma multiforme. Biochem Genet. 2016;54(5):573\u2013618.","journal-title":"Biochem Genet"},{"issue":"10","key":"4378_CR46","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.30490","volume":"123","author":"P Rousselot","year":"2017","unstructured":"Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, et al. Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study. Cancer. 2017;123(10):1791\u20139.","journal-title":"Cancer"},{"issue":"2","key":"4378_CR47","first-page":"121","volume":"1","author":"G Martinelli","year":"2007","unstructured":"Martinelli G, Iacobucci I, Soverini S, Palandri F, Castagnetti F, Rosti G, et al. Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. Biologics. 2007;1(2):121\u20137.","journal-title":"Biologics"},{"issue":"3","key":"4378_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445\u201353.","journal-title":"Biochim Biophys Acta"},{"key":"4378_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2016.10.017","volume":"170","author":"H Koepsell","year":"2017","unstructured":"Koepsell H. The Na(+)-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther. 2017;170:148\u201365.","journal-title":"Pharmacol Ther"},{"issue":"30","key":"4378_CR50","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112(30):E4111\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4378_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12672-023-00719-x","volume":"14","author":"W Wu","year":"2023","unstructured":"Wu W, Wang Y, Xie J, Fan S. Empagliflozin: a potential anticancer drug. Discov Oncol. 2023;14(1):127.","journal-title":"Discov Oncol"},{"issue":"1","key":"4378_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4378_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1365-2141.2003.04746.x","volume":"124","author":"M Mamani-Matsuda","year":"2004","unstructured":"Mamani-Matsuda M, Moynet D, Molimard M, Ferry-Dumazet H, Marit G, Reiffers J, et al. Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 2004;124(2):141\u201350.","journal-title":"Br J Haematol"},{"issue":"2","key":"4378_CR54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10549-010-0822-2","volume":"125","author":"M Shi","year":"2011","unstructured":"Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, et al. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat. 2011;125(2):351\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4378_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/1940-6207.CAPR-14-0193","volume":"8","author":"A Chang","year":"2015","unstructured":"Chang A, Yeung S, Thakkar A, Huang KM, Liu MM, Kanassatega RS, et al. Prevention of skin carcinogenesis by the beta-blocker carvedilol. Cancer Prev Res (Phila). 2015;8(1):27\u201336.","journal-title":"Cancer Prev Res (Phila)"},{"key":"4378_CR56","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6085515","author":"MY Medina-Pizano","year":"2022","unstructured":"Medina-Pizano MY, Medina-Rosales MN, Martinez-Hernandez SL, Aldaba-Muruato LR, Macias-Perez JR, Sanchez-Aleman E, et al. Protective effect of curcumin against doxazosin-and carvedilol-induced oxidative stress in HepG2 cells. Oxid Med Cell Longev. 2022. https:\/\/doi.org\/10.1155\/2022\/6085515.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"4378_CR57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28\u201339.","journal-title":"Nat Rev Cancer"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04378-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:03:32Z","timestamp":1788523412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04378-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4378"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04378-0","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"303"}}